These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15976726)

  • 41. [Uveitic macular edema].
    Fardeau C; Champion E; Massamba N; LeHoang P
    J Fr Ophtalmol; 2015 Jan; 38(1):74-81. PubMed ID: 25547721
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
    Morris DS; Gavin MP; Sturrock RD
    Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763
    [No Abstract]   [Full Text] [Related]  

  • 43. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial.
    Suhler EB; Smith JR; Giles TR; Lauer AK; Wertheim MS; Kurz DE; Kurz PA; Lim L; Mackensen F; Pickard TD; Rosenbaum JT
    Arch Ophthalmol; 2009 Jun; 127(6):819-22. PubMed ID: 19506209
    [No Abstract]   [Full Text] [Related]  

  • 44. [Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis].
    Zierhut M; Stübiger N; Aboalchamat W; Landenberger H; Bialasiewicz AA; Engelmann K
    Ophthalmologe; 2001 Jul; 98(7):647-51. PubMed ID: 11490743
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
    Tabbara KF; Al-Hemidan AI
    Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Uveitic cystoid macular edema: intravitreal triamcinolone].
    Feucht M; Sturm V; Weissmann J; Richard G; Pressmar S
    Klin Monbl Augenheilkd; 2007 Jan; 224(1):62-5. PubMed ID: 17260323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug-induced inflammation in patients on TNFα inhibitors.
    Cunningham ET; Pasadhika S; Suhler EB; Zierhut M
    Ocul Immunol Inflamm; 2012 Feb; 20(1):2-5. PubMed ID: 22324894
    [No Abstract]   [Full Text] [Related]  

  • 48. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
    Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D
    Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Uncovering the risks of immunosuppressive therapy in patients with uveitis.
    Goldstein DA
    Arch Ophthalmol; 2009 Jun; 127(6):799-800. PubMed ID: 19506201
    [No Abstract]   [Full Text] [Related]  

  • 50. New indications for treatment of chronic inflammation by TNF-alpha blockade.
    Reimold AM
    Am J Med Sci; 2003 Feb; 325(2):75-92. PubMed ID: 12589232
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Anti-TNF-α treatment for uveitis. Analysis of the current situation].
    Pleyer U; Mackensen F; Winterhalter S; Stübiger N
    Ophthalmologe; 2011 Jan; 108(1):13-20. PubMed ID: 21181169
    [TBL] [Abstract][Full Text] [Related]  

  • 52. General principles for the treatment of non-infectious uveitis.
    Díaz-Llopis M; Gallego-Pinazo R; García-Delpech S; Salom-Alonso D
    Inflamm Allergy Drug Targets; 2009 Sep; 8(4):260-5. PubMed ID: 19754409
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Conventional immunosuppressive therapy in severe Behcet's Uveitis: the switch rate to the biological agents.
    Celiker H; Kazokoglu H; Direskeneli H
    BMC Ophthalmol; 2018 Oct; 18(1):261. PubMed ID: 30290779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
    Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues.
    Cordero-Coma M; Salazar-Méndez R; Yilmaz T
    Expert Opin Drug Saf; 2015; 14(9):1353-71. PubMed ID: 26118392
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical trials in noninfectious uveitis.
    Kim JS; Knickelbein JE; Nussenblatt RB; Sen HN
    Int Ophthalmol Clin; 2015; 55(3):79-110. PubMed ID: 26035763
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunologic mechanisms of uveitis. New targets for immunomodulation.
    Whitcup SM; Nussenblatt RB
    Arch Ophthalmol; 1997 Apr; 115(4):520-5. PubMed ID: 9109763
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Research update of anti-TNF-α biologic agents in the treatment of uveitis].
    Fan F; Zhou M; Luo Y
    Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):285-8. PubMed ID: 23866712
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Uveitis associated with juvenile idiopathic arthritis : Optimization of immunomodulatory therapy].
    Heiligenhaus A; Tappeiner C; Walscheid K; Heinz C
    Ophthalmologe; 2016 May; 113(5):391-7. PubMed ID: 27142035
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.